AI Article Synopsis
- * The main trigger for HS involves hyperkeratosis (thickening) of hair follicles in specific skin glands, but the exact cause is still not fully understood.
- * Since the approval of the drug Adalimumab in 2015, research has focused on the role of certain inflammatory cytokines in HS and identifying new treatment options.
Article Abstract
Hidradenitis suppurativa (HS) is an immune-mediated inflammatory disorder characterized by deep-seated nodules, abscesses, sinus tracts and scars localized in the intertriginous areas. It is accompanied by pain, malodourous secretion and a dramatically decreased quality of life. Although the pathogenesis has not been entirely elucidated, the primary event is follicular hyperkeratosis of the pilosebaceous apocrine unit. Since the registration of the tumor necrosis factor-alpha inhibitor Adalimumab in 2015, several cytokines have been implicated in the pathomechanism of HS and the research of novel therapeutic targets has been intensified. We provide an update on the inflammatory cytokines with a central role in HS pathogenesis and the most promising target molecules of future HS management.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179439 | PMC |
| http://dx.doi.org/10.3390/ijms24098428 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hidradenitis Suppurativa.
Annu Rev Med
January 2025
Division of Dermatology, University College Cork, The National University of Ireland, Cork, Ireland; email:
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by the formation of nodules, abscesses, and fistulae at intertriginous sites. Pain, pruritus, malodor, and suppuration have a significant impact on quality of life for HS patients. Prevalence figures vary greatly in the literature from 0.
View Article and Find Full Text PDFReal-World Experience of Clascoterone Cream 1% in Acne Management: Case Series and Canadian Experience.
Clin Cosmet Investig Dermatol
January 2025
Western University, London, ON, Canada.
Acne vulgaris is a globally prevalent dermatological condition associated with substantial physical and psychological burden. Although acne typically presents during adolescence, it is a chronic condition that also affects many adults. Despite the spectrum of treatments available for acne, limitations in tolerability and safety concerns can present challenges for the use of conventional medications in clinical practice.
View Article and Find Full Text PDFMarginal Zone Lymphoma in a Case of Hidradenitis Suppurativa Treated With Adalimumab Therapy.
J Community Hosp Intern Med Perspect
January 2025
Department of Internal Medicine, MedStar Health Franklin Square Medical Center, Baltimore, USA.
Marginal zone lymphoma has seldom been described in relation to adalimumab used for treatment of hidradenitis suppurativa. Although studies have shown an increased risk of lymphoma with adalimumab, most of these studies were done in patients with underlying inflammatory bowel disease or rheumatoid arthritis where the disease itself presents as a confounder for lymphoma. Our case described adds to the role of chronic anti-TNF alpha therapy as a possible etiology of lymphoma.
View Article and Find Full Text PDFNew horizons in the treatment of psoriasis: Modulation of gut microbiome.
Heliyon
January 2025
Department of Medical Microbiology, Tehran University of Medical Sciences, Tehran, Iran.
The last decennia have witnessed spectacular advances in our knowledge about the influence of the gut microbiome on the development of a wide swathe of diseases that extend beyond the digestive tract, including skin diseases like psoriasis, atopic dermatitis, acne vulgaris, rosacea, alopecia areata, and hidradenitis suppurativa. The novel concept of the gut-skin axis delves into how skin diseases and the microbiome interact through inflammatory mediators, metabolites, and the intestinal barrier. Elucidating the effects of the gut microbiome on skin health could provide new opportunities for developing innovative treatments for dermatological diseases.
View Article and Find Full Text PDFDual immunomodulator therapy with adalimumab and upadacitinib to treat recalcitrant hidradenitis suppurativa.
JAAD Case Rep
February 2025
Division of Dermatology, Albert Einstein College of Medicine, Bronx, New York.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!